Differin (Adapalene) Patent Expiration, LOE Window & CMS Spending

Differin (Adapalene) by Galderma Laboratories: FDA Orange Book LOE 2028-05-31, 7 AB generics, $113K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGalderma Laboratories
FDA Application & PathwayN020380 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-05-31
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$113K
2024 Medicare Part D Spend$58K
2024 Medicaid Spend$56K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel